Scott Brun, M.D., appointed to Jasper Board as R&D Committee Chair; Klein resigns

Jasper Therapeutics, Inc.

Scott Brun, M.D., appointed as Class I director effective June 20, 2023; chairs R&D Committee, serves on Compensation Committee.
Dr. Brun has over 20 years pharma R&D leadership, including AbbVie, Abbott, and Horizon Therapeutics.
Lawrence Klein, Ph.D., resigned effective June 20, 2023, due to his recent appointment as a Partner at Versant Ventures.
Vishal Kapoor appointed to Audit and Compensation Committees.
Dr. Brun receives initial option grant of 94,000 shares vesting over 4 years under Director Compensation Policy.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Scott Brun

Class I Director

JSPR · Jasper Therapeutics, Inc.

Effective: 2023-06-20
Filed: June 20, 2023, 7:59 PM ET

Effective June 20, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Scott Brun, M.D., as a Class I director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Brun was appointed as Class I Director at Jasper Therapeutics, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

Effective June 20, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Scott Brun, M.D., as a Class I director of the Company.

View on SEC.gov

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-050029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.